Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27033217 | 0.94 | NR1H2 (0.49) | NR1H2FAAHNAMPTGPR119USP2 | |
| SCHEMBL16629053 | 0.90 | NR1H2 (0.54) | NR1H2FAAHNAMPTGPR119USP2 | |
| SCHEMBL26470694 | 0.88 | NR1H2 (0.51) | NR1H2FAAHNAMPTGPR119USP2 | |
| SCHEMBL16921334 | 0.88 | NR1H2 (0.51) | NR1H2FAAHNAMPTGPR119USP2 | |
| SCHEMBL31747505 | 0.88 | NR1H2 (0.51) | NR1H2FAAHNAMPTGPR119USP2 | |
| SCHEMBL544238 | 0.86 | FAAH (0.58) | FAAHGPR119KDM4EPKMITGB3 | |
| SCHEMBL28626485 | 0.86 | MEN1 (0.49) | NR1H2FAAHGPR119ITGB1ITGA4 | |
| SCHEMBL26547585 | 0.84 | GPR119 (0.48) | NR1H2FAAHGPR119KDM4EPKM | |
| SCHEMBL15297794 | 0.84 | NR1H2 (0.54) | NR1H2FAAHNAMPTGPR119USP2 | |
| SCHEMBL7401533 | 0.84 | NR1H2 (0.58) | NR1H2FAAHNAMPTGPR119USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-9636298-B2 | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs | METHYLGENE INC (CA) | 2017-05-02 | — | — | US | disclosed |
| US-9636298-B2 | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs | METHYLGENE INC (CA) | 2017-05-02 | — | — | US | disclosed |
| US-9636298-B2 | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs | METHYLGENE INC (CA) | 2017-05-02 | — | — | US | disclosed |
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | METHYLGENE INC (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | METHYLGENE INC (CA) | 2015-07-23 | — | — | US | disclosed |
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | METHYLGENE INC (CA) | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | HDAC5, HDAC1, HDAC3 | NR1H2 2045/4885FAAH 1677/4885NAMPT 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.